NZ522788A - Prolonged therapeutic effect of mixtures of C16 and C18 phospholipid derivatives of valproic acid (DP-VPA) in anti-convulsant medicaments - Google Patents

Prolonged therapeutic effect of mixtures of C16 and C18 phospholipid derivatives of valproic acid (DP-VPA) in anti-convulsant medicaments

Info

Publication number
NZ522788A
NZ522788A NZ522788A NZ52278801A NZ522788A NZ 522788 A NZ522788 A NZ 522788A NZ 522788 A NZ522788 A NZ 522788A NZ 52278801 A NZ52278801 A NZ 52278801A NZ 522788 A NZ522788 A NZ 522788A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutically acceptable
valproic acid
acceptable derivative
vpa
pharmaceutical composition
Prior art date
Application number
NZ522788A
Other languages
English (en)
Inventor
Alexander Kozak
Original Assignee
Dpharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dpharm Ltd filed Critical Dpharm Ltd
Publication of NZ522788A publication Critical patent/NZ522788A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NZ522788A 2000-07-12 2001-07-10 Prolonged therapeutic effect of mixtures of C16 and C18 phospholipid derivatives of valproic acid (DP-VPA) in anti-convulsant medicaments NZ522788A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/614,271 US6313106B1 (en) 1995-06-07 2000-07-12 Phospholipid derivatives of valproic acid and mixtures thereof
PCT/IL2001/000629 WO2002007669A2 (en) 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof

Publications (1)

Publication Number Publication Date
NZ522788A true NZ522788A (en) 2005-04-29

Family

ID=24460534

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ522788A NZ522788A (en) 2000-07-12 2001-07-10 Prolonged therapeutic effect of mixtures of C16 and C18 phospholipid derivatives of valproic acid (DP-VPA) in anti-convulsant medicaments

Country Status (20)

Country Link
US (2) US6313106B1 (https=)
EP (1) EP1315506B1 (https=)
JP (1) JP5140224B2 (https=)
KR (1) KR100801213B1 (https=)
CN (1) CN100536851C (https=)
AT (1) ATE461697T1 (https=)
AU (2) AU7096201A (https=)
BR (1) BR0112337A (https=)
CA (1) CA2415354C (https=)
CY (1) CY1110113T1 (https=)
CZ (1) CZ305745B6 (https=)
DE (1) DE60141636D1 (https=)
DK (1) DK1315506T3 (https=)
ES (1) ES2343403T3 (https=)
HU (1) HU229320B1 (https=)
IL (1) IL153147A0 (https=)
MX (1) MXPA03000326A (https=)
NZ (1) NZ522788A (https=)
PT (1) PT1315506E (https=)
WO (1) WO2002007669A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
US6518311B2 (en) * 1997-07-09 2003-02-11 D-Pharm Ltd. Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US7582678B2 (en) 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
CN1649600A (zh) 2002-02-28 2005-08-03 A&D生物科学公司 氟西汀及类似物的糖醛酰胺、苷和原酸酯苷及其应用
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
CA2484891A1 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
GB2460976B (en) * 2005-03-24 2010-02-17 John Marcell Davis Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
WO2007028030A2 (en) * 2005-09-02 2007-03-08 Picobella, Llc Oncogenic regulatory rnas for diagnostics and therapeutics
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
KR200451744Y1 (ko) * 2008-10-10 2011-01-10 이종희 휴대용 운동기구
JP2015533114A (ja) * 2012-05-08 2015-11-19 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物及び方法
CN104230981B (zh) * 2013-06-20 2016-05-18 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的制备方法
PT3429580T (pt) * 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
CN108659038B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 1-硬脂酰-2-丙戊酰-sn-甘油-3-磷脂酰胆碱的多晶型物及制备方法
CN108659037B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的多晶型物及制备方法
KR101864085B1 (ko) * 2017-09-22 2018-06-01 동아대학교 산학협력단 발프로산 유도체, 이의 제조방법 및 이를 포함하는 항경련제
CN110407867A (zh) * 2018-04-28 2019-11-05 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的新晶型及其制备方法
CN114344303B (zh) * 2022-01-13 2023-05-09 江苏海洋大学 一种新型精神药物固体分散体及制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654370A (en) * 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4988731A (en) 1979-08-20 1991-01-29 Abbott Laboratories Sodium hydrogen divalproate oligomer
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
IT1201149B (it) 1987-01-14 1989-01-27 Indena Spa Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
ATE151467T1 (de) 1987-11-30 1997-04-15 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
DE3801587A1 (de) 1988-01-21 1989-08-03 Hoechst Ag Neue aminosaeureglyceride, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
CA2049028A1 (en) 1989-03-07 1990-09-08 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
JPH03133987A (ja) 1989-10-18 1991-06-07 Kowa Yakuhin Kogyo Kk ２‐マイトマイシンｃ‐スクシニル‐１，３‐ジパルミトイルグリセロールおよびその製造法
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
CH679856A5 (https=) 1990-07-04 1992-04-30 Lonza Ag
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
AU668873B2 (en) 1991-07-12 1996-05-23 Chimerix, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6015834A (en) 1992-10-20 2000-01-18 Toronto Neuroprotection Group In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer
IL105244A (en) 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
KR100301803B1 (ko) 1998-06-05 2001-09-22 김영환 박막트랜지스터 및 그의 제조방법

Also Published As

Publication number Publication date
DE60141636D1 (de) 2010-05-06
IL153147A0 (en) 2003-06-24
CA2415354A1 (en) 2002-01-31
PT1315506E (pt) 2010-05-17
AU2001270962B2 (en) 2006-03-16
DK1315506T3 (da) 2010-05-31
HUP0302635A2 (hu) 2003-11-28
BR0112337A (pt) 2004-06-08
US6313106B1 (en) 2001-11-06
JP2004509854A (ja) 2004-04-02
JP5140224B2 (ja) 2013-02-06
EP1315506A2 (en) 2003-06-04
AU7096201A (en) 2002-02-05
KR100801213B1 (ko) 2008-02-05
CN1774252A (zh) 2006-05-17
KR20030034099A (ko) 2003-05-01
CA2415354C (en) 2009-09-29
AU2001270962B8 (en) 2006-08-10
HUP0302635A3 (en) 2007-06-28
ATE461697T1 (de) 2010-04-15
WO2002007669A3 (en) 2003-01-09
MXPA03000326A (es) 2004-12-13
WO2002007669A2 (en) 2002-01-31
EP1315506B1 (en) 2010-03-24
ES2343403T3 (es) 2010-07-30
CN100536851C (zh) 2009-09-09
CZ305745B6 (cs) 2016-03-02
US20040033987A1 (en) 2004-02-19
CZ200386A3 (cs) 2003-06-18
EP1315506A4 (en) 2005-03-30
CY1110113T1 (el) 2015-01-14
HU229320B1 (en) 2013-10-28

Similar Documents

Publication Publication Date Title
CA2415354C (en) Phospholipid derivatives of valproic acid and mixtures thereof
AU2001270962A1 (en) Phospholipid derivatives of valproic acid and mixtures thereof
DE69232101T2 (de) Lipid-derivate von phosphonsäuren für liposomale inkorporation und verwendungsverfahren
JP7610208B2 (ja) 足場部分から調製した脂質結合体
WO1991016920A1 (en) Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
US20220273682A1 (en) Acefapc for the treatment of acetylcholine-dependent diseases
EP1140017B1 (en) Water-insoluble drug delivery system
JP2001509500A (ja) 分岐鎖脂肪酸、それらの誘導体、および中枢神経系障害の処置における使用
JP3801225B2 (ja) アミノアルコール類の塩およびこれを含有する医薬処方物
CA2667150A1 (en) Omega-3 lipid compounds
US5202313A (en) Bilobalide derivatives, their applications and formulations containing them
KR20220140563A (ko) 카나비노이드 설페이트 에스테르, 이들의 염 및 이의 사용
US20020042445A1 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
JP2019529517A (ja) ニトロソ化およびアルキル化反応を媒介するニトロアルケンの新規可逆的窒素酸化物誘導体
IL153147A (en) Pharmaceutical compositions comprising phospholipid conjugates of valproic acid or derivatives thereof
KR100263085B1 (ko) 신규의 알카로이드 유도체, 이의 용도 및 이를 함유한 제약적 조성물
DE102015201148B4 (de) Verwendung von Phenylphosphaten und deren Prodrugs als Arzneimittel in der Krebstherapie
KR840001917B1 (ko) 글리세릴 1,2-비스-(디-n-프로필아세테이트)와 글리세릴 1,3-비스-(디-n-프로필아세테이트) 혼합물의 제조방법
JP2025505177A (ja) リボースリンカーおよびその複合体
WO2016116603A1 (de) Neuartige phenylphosphate und deren verwendung als arzneimittel
EP4216960A1 (en) Compound for use in the treatment of protozoal diseases and process for production of said compound

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 10 JUL 2021 BY CPA GLOBAL

Effective date: 20140605

EXPY Patent expired